skip to Main Content

Canadian biotech sector makes strong showing at BIO2013

Every six weeks, MaRS Innovation’s marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI’s activities or one of our start-up companies. You can read the original post on the MaRS blog.

Downtown Chicago skyline in late April
Chicago‘s famous downtown skyline during the 2013 BIO Convention.

Nearly 14,000 delegates—representing over 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and more than 60 countries—attended the 2013 BIO International Convention from April 22 to 26, 2013.

The event drew biotechnologists, pharmaceutical industry executives and life sciences researchers, along with sector-based organizations and associations, to Chicago.

According to a press release issued by the conference organizers, BIO 2013 offered “a record number of partnering meetings and panel sessions on the latest science, policy issues and business opportunities and challenges facing the biotechnology industry.”

Continue Reading

Merck invests in pan-Canadian life sciences research innovation sector

A $4-million public-private partnership will promote research innovation involving three academic commercialization centres in Canada

CHICAGO, Illinois April 22, 2013Merck Canada will be announcing today at the BIO International Convention that it is reinforcing its commitment to the Canadian life sciences research innovation sector.

Merck will provide $4 million in funding to the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centres of Excellence for Commercialization and Research (CECRs) based in Ontario and in British Columbia.

This partnership announcement was covered by PEHub.

IRICoR will work in conjunction with MaRS Innovation and the Centre for Drug Research and Development (CDRD) to identify, develop and commercialize technologies in healthcare. All three CECR institutions – identified as CECR in 2008 by the federal government – share a common objective: facilitating and accelerating the commercialization of research breakthroughs that will improve the quality of life of Canadians and others around the world.

Continue Reading
Back To Top